Skip to content

Pulse Oximeter for Sleep Evaluation

Ring-type Pulse Oximeter for Evaluation for Sleep Assessment Study (ROSA Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04612114
Acronym
ROSA
Enrollment
40
Registered
2020-11-02
Start date
2020-07-21
Completion date
2022-04-30
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

obstructive sleep apnea, pulse oximeter, polysomnography

Brief summary

The investigators will conduct this study to validate Belun Ring for sleep assessment. The investigators will compare Belun Ring data collection and overnight in-lab polysomnography (PSG) measures of SDB and sleep architecture in adults with OSA symptoms. The investigators propose to recruit a total of 40 participants with symptoms of obstructive sleep apnea. The investigators will i) validate the overall accuracy, sensitivity and specificity of Belun Ring to assess SDB and sleep architecture, using PSG analysis as a gold standard.

Interventions

DIAGNOSTIC_TESTBelun Ring

Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.

Sponsors

Belun Technology Company Limited
CollaboratorOTHER
Stanford University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

1. Age between 18 to 80 years old. Ideally balanced for sex and age (18 to 80 years old) * No more than 75% of subjects in one bin of: (male, female) * No more than 50% of subjects in one age-group (18-29, 30-39, 40-49, 50-59, 60-80) 2. Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.) 3. Without any unstable medical or psychiatric co-morbidities that would be expected to interfere with the study. 4. If taking any medication, must be on a stable dose of medication for a month 5. Able to read and understand English

Exclusion criteria

1. Presence of any significant systemic or unstable medical condition which could lead to difficulty complying with the protocol, suicidality, current regular use of psychiatric medications, opiates, or thyroid medications, dementia, current substance abuse, post-traumatic or psychotic disorders, bipolar disorder; any significant neurologic disease, including possible and probable dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of significant head trauma, history of alcohol or substance use disorder within the past 2 years (DSM V criteria); 2. If positive airway pressure (PAP) titration study or split night study (diagnostic and PAP titration study combined) 3. Under 18 or over 80 years of age

Design outcomes

Primary

MeasureTime frameDescription
Validation with gold-standard polysomnography (PSG) recordingthrough study completion, an average of 1 yearConcordance rate of respiratory disturbance index (RDI) from Belun Ring and apnea-hypopnea Index (AHI) from PSG

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026